2-(1-methylpropoxy)pyridine | 228103-63-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(1-methylpropoxy)pyridine
• 英文别名: 2-Butan-2-yloxypyridine
• CAS: 228103-63-7
• 化学式: C₉H₁₃NO
• mdl: MFCD18802427
• 分子量: 151.208
• InChiKey: BHUMJMSNCNKZGY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.444
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(1-methylpropoxy)pyridine 在 bis(1,5-cyclooctadiene)iridium(I) tetrafluoroborate 作用下， 以 氯苯 为溶剂， 反应 24.0h， 以64%的产率得到1-(1-methylpropyl)pyridin-2(1H)-one
  参考文献：
  名称：

  Ir(I)-Catalyzed Synthesis of N-Substituted Pyridones from 2-Alkoxypyridines via C–O Bond Cleavage

  摘要：

  A cationic Ir(I) complex-catalyzed O-to-N-alkyl migration in 2-alkoxypyridines bearing a secondary alkyl group on the oxygen atom by C-O bond cleavage is described. The present transformation gave various N-alkylpyridones in moderate to good yields. The addition of sodium acetate played a key role in suppressing beta-hydrogen elimination.

  DOI：

  10.1021/ol400557z
• 作为产物：
  描述：

  2-氯吡啶 、 仲丁醇 在 potassium tert-butylate 作用下， 以 1,4-二氧六环 为溶剂， 反应 24.0h， 以49%的产率得到2-(1-methylpropoxy)pyridine
  参考文献：
  名称：

  Ir(I)-Catalyzed Synthesis of N-Substituted Pyridones from 2-Alkoxypyridines via C–O Bond Cleavage

  摘要：

  A cationic Ir(I) complex-catalyzed O-to-N-alkyl migration in 2-alkoxypyridines bearing a secondary alkyl group on the oxygen atom by C-O bond cleavage is described. The present transformation gave various N-alkylpyridones in moderate to good yields. The addition of sodium acetate played a key role in suppressing beta-hydrogen elimination.

  DOI：

  10.1021/ol400557z

文献信息

• Streamlined Synthesis of the Bippyphos Family of Ligands and Cross-Coupling Applications
  作者：Gregory J. Withbroe、Robert A. Singer、Janice E. Sieser

  DOI：10.1021/op7002858

  日期：2008.5.1

  the efficient preparation of Bippyphos, 1. The key precursor to Bippyphos, 5, was prepared via a one-pot bromination of diketone 2 followed by alkylation with pyrazole and condensation with phenylhydrazine. Lithiation of 5 and trapping with di-tert-butylchlorophosphine afforded Bippyphos, 1. Using this approach we have prepared several derivatives of Bippyphos to probe the structure and activity relationships

  我们描述了Bippyphos，1的有效制备方法。Bippyphos的关键前体5是通过二锅2的一锅溴化反应，然后用吡唑烷基化并与苯肼缩合制备的。5的锂化并用二叔丁基氯膦捕获，得到Bippyphos，1。使用这种方法，我们已经制备了Bippyphos的几种衍生物，以探测该膦配体家族的结构和活性之间的关系。我们还证明了这些配体在钯催化的胺化反应和其他交叉偶联反应中的效用。
• NON-AQUEOUS SECONDARY BATTERY AND NON-AQUEOUS ELECTROLYTE
  申请人：Asahi Kasei Kabushiki Kaisha

  公开号：EP4009398A1

  公开（公告）日：2022-06-08

  Provided is a non-aqueous secondary battery that includes a positive electrode, a negative electrode, a separator, and a non-aqueous electrolyte. The positive electrode includes LiNixCoyMnzO2 (0.7 < x < 0.9, 0 < y < 0.2, 0 < z < 0.2) as a lithium-containing metal oxide, and when the positive electrode before and after cycle testing of the non-aqueous secondary battery is analyzed by powder X-ray diffraction using Cu-Kα radiation, the rate of change of the c-axis lattice constant is 1.0% or less. The non-aqueous electrolyte includes 5-20% by volume of acetonitrile and has an ion conductivity of at least 10 mS/cm and less than 15 mS/cm at 20°C.

  本文提供了一种非水二次电池，它包括正极、负极、隔膜和非水电解液。正极包括作为含锂金属氧化物的 LiNixCoyMnzO2 (0.7 < x < 0.9, 0 < y < 0.2, 0 < z < 0.2)，当使用 Cu-Kα 辐射对非水性二次电池循环测试前后的正极进行粉末 X 射线衍射分析时，c 轴晶格常数的变化率为 1.0% 或更小。非水电解液包括 5-20%（体积）的乙腈，在 20°C 时离子电导率至少为 10 mS/cm，小于 15 mS/cm。
• PROTEASE INHIBITORS
  申请人：Smithkline Beecham

  公开号：EP0977743A1

  公开（公告）日：2000-02-09
• Non-Aqueous Secondary Battery and Non-Aqueous Electrolyte
  申请人：Asahi Kasei Kabushiki Kaisha

  公开号：US20220293929A1

  公开（公告）日：2022-09-15

  Provided is a non-aqueous secondary battery that includes a positive electrode, a negative electrode, a separator, and a non-aqueous electrolyte. The positive electrode includes LiNi x Co y Mn z O 2 (0.7
• [EN] PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTEASES
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：WO1998049152A1

  公开（公告）日：1998-11-05

  (EN) Compounds of formula (I), wherein Rl is an aromatic or a heteroaromatic ring; R2 and R3 are H, C1-C8alkyl, aryl, arylC1-C8alkyl, or heteroaryl; R4 is an aromatic or a heteroaromatic ring or an amine; W, X, Y, are independently selected from the group consisting of CH, N, S, or O, provided that at least one of W, X, and Y is a heteroatom, which inhibit protease, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease therewith.(FR) L'invention concerne des composés de formule (I), dans laquelle R1 est un cycle aromatique ou hétéroaromatique, R2 et R3 sont H, alkyle C1-8, aryle, aryl-alkyleC1-8 ou hétéroaryle; R4 est un cycle aromatique ou hétéroaromatique ou une amine, W, X, Y sont choisis séparément dans le groupe constitué de CH, N, S ou O, à condition qu'au moins un parmi W, X et Y soit un hétéroatome, lesdits composés inhibant la protéase, dont la cathépsine K. L'invention porte aussi sur des compositions pharmaceutiques contenant lesdits composés, sur des méthodes de traitement à l'aide desdites compositions, de maladies se manifestant par une perte osseuse excessive ou une dégradation du cartilage ou de la matrice, dont l'ostéoporose, l'affection gingivale telle que la gingivite et la parodontose, l'arthrite, l'arthrose et la polyarthrite rhumatoïde, la maladie osseuse de Paget, l'hypercalcémie maligne et la maladie métabolique des os.